Slide 1

RELEVANCE Study Design

(Rituximab and LEnalidomide versus Any ChEmotherapy

•

Median follow-up of 37.9 months, the interim progression-free survival (PFS) by

an independent review committee was 77% in the R

arm versus 78% in the R-

chemo arm (HR 1.10, 95% CI [0.85, 1.43]; p = 0.48).

•

Discontinuations due to treatment were also similar between the two groups,

with 157 in the R

group versus 146 in the R-chemo group, with the most

frequent reasons due to progression and toxicity.